4/A: Ionis Pharmaceuticals CEO Brett Monia Amends Form 4 Filing to Correctly Report Stock Sale
SEC Filing
Brett Monia, CEO of Ionis Pharmaceuticals, amended a previous Form 4 filing to accurately reflect the number of shares sold on February 2, 2024.
Summary
- Brett Monia, the CEO of Ionis Pharmaceuticals, filed an amendment to a Form 4, which reports changes in beneficial ownership of securities.
- The amendment corrects the number of shares sold on February 2, 2024.
- The corrected filing shows that 23,907 shares of common stock were sold at a weighted average price of $49.3725.
- The sales occurred in multiple transactions with prices ranging from $49.22 to $49.51.
- Following the reported transaction, Monia beneficially owns 173,732 shares.
- The original Form 4 filed on February 2, 2024, reported 23,501 restricted stock units sold.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing amendment, indicating a correction of previously reported information. It doesn't inherently suggest positive or negative sentiment, but accuracy in reporting is generally viewed favorably.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. Amendments are not uncommon and can occur for various reasons, including correcting errors in the original filing.
Key Dates
| Date | Description |
|---|---|
| 02/02/2024 | Date of original transaction and initial Form 4 filing. |
| 02/02/2024 | Date of amended Form 4 filing. |
| 09/04/2024 | Date of signature on the amended Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.